|
Mutation Information
|
Mutation Site
|
M184V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
lamivudine (3TC);emtricitabine(FTC) |
|
Country
|
Cameroon |
Literature Information
|
PubMed PMID
|
30871487
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2019 |
|
Journal
|
BMC infectious diseases |
|
Title
|
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. |
|
Author
|
Takou D,Fokam J,Teto G,Santoro MM,Ceccherini-Silberstein F,Nanfack AJ,Sosso SM,Dambaya B,Salpini R,Billong SC,Gori C,Fokunang CN,Cappelli G,Colizzi V,Perno CF,Ndjolo A |
|
Evidence
|
The very high frequency of M184 V (> 80%) underscores the utility of this mutation as an indicator of therapeutic compliance in clinical practice for patients receiving any regimen containing 3TC or FTC.
|
|
|
HIV Mutation Detail Information